NASDAQ: EWTX

Edgewise Therapeutics (EWTX) Stock Analysis & Forecast

Nov 13 close

$45.93+0.11 (+0.2%)

Gekko Brief

AI summaryNov 9 close

Edgewise Therapeutics moved this week on a cluster of catalysts. Shares jumped 12% on a report of takeover interest, with an "uncooked" alert suggesting the company hired advisers for a sales process involving two European pharmas and one US-listed company. Separately, the company announced a productive End-of-Phase 2 meeting with the FDA for EDG-7500 in hypertrophic cardiomyopathy, with the STRATUS-HCM Phase 3 protocol submitted and featuring tolerability-based dose escalation. Third-quarter results showed EPS of $9.65 against an estimate of ($0.53), with net income of $1.17 billion driven largely by the $1.396 billion upfront sale of the sevasemten program to Servier, a drug that had missed trial endpoints. Management also confirmed plans for Phase 2 EQUINOX-HFpEF dosing and upcoming investor conference appearances.

EWTX closed at $48.74, up 8.2% on the day, sitting above both its 50-day ($40.97) and 200-day ($36.65) averages, with the shorter average above the longer one. The GekkoIndex reading of 39.5 places the stock in the Distribution zone, down 22.4 points over five sessions. Price sits 14.7% above the $42.48 Gekko Fair Value estimate.

Over the next 20 trading days, the next earnings report is not due until 25 February 2027, 107 days out. Options activity shows 1 unusual signal in the last 30 days, with call premium of $1,112,230 against no put premium. Seasonally, the stock has averaged a 4.3% move over this stretch across 5 years, rising in 3 of them. Analyst consensus stands at 9 buy and 2 hold ratings among 11 firms, with a $54 consensus target.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Edgewise Therapeutics price vs fair value

$45.93$43.29Nov ’25May ’26Nov ’26
Close $45.93200-day averageGekko Fair Value $43.29

Edgewise Therapeutics quick facts

Market cap
$4.94B
P/E ratio
5.5
Forward P/E
—
EPS, TTM
$8.38
Revenue, TTM
$0
Profit margin
0%
Dividend yield
—
Beta
0.40
Volume
1.16M avg 1.67M
1-year return
+117.0%
Typical daily move
±7.1%
Typical 20-day move
±10.7%
50-day average
$41.33
200-day average
$37.01
Next earnings
Feb 25
Shares outstanding
109.5M
52-week range
$19.76$48.78

Edgewise Therapeutics swing-trade checklist

Edgewise Therapeutics scores 3 supportive, 1 mixed and 2 headwinds across the 6 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

3 supportive1 mixed2 headwinds

  • Trendsupportive

    Above 50 and 200-day

    Close $45.93 is above the 50-day ($41.33) and 200-day ($37.01) averages, and the 50-day is above the 200-day.

    See the chart
  • GekkoIndexmixed

    49.9, Neutral

    Reading 49.9 is in the Neutral zone.

    See the GekkoIndex
  • Fair valueheadwind

    6.1% above

    Price is 6.1% above Gekko Fair Value (more than 5% above).

    See fair value
  • Smart moneysupportive

    Leans bullish

    Last 30 days: 1 unusual options signal.

    See smart money
  • Earnings risksupportive

    Reports in 102 days

    Next report Feb 25, 2027, 102 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalityheadwind

    −5.5% on average

    From this point in the calendar, the next 20 trading days averaged −5.5% over 5 years, rising in 2 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Edgewise Therapeutics stock chart and price history

Edgewise Therapeutics closed at $45.93 on Nov 13, 2026, +117.0% over the past year, inside a 52-week range of $19.76 to $48.78.

Close50-day average200-day averageVolume
Edgewise Therapeutics share price, past year, with 50-day and 200-day moving averages and volume$20$30$40$50DecJan 2026FebMarAprMayJunJulAugSepOctNov45.93

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+20.2%
3 months
+4.3%
6 months
+38.8%
1 year
+117.0%
The full EWTX chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open EWTX in Gekko

Follow Edgewise Therapeutics through every session

Put EWTX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track EWTX in GekkoFree for 7 days. No credit card required.

About Edgewise Therapeutics

Edgewise Therapeutics works on small-molecule drugs aimed at muscle and skeletal diseases that stem from genetic causes. Its furthest-along candidate, EDG-5506, is a pill designed to address the root genetic mechanisms behind dystrophinopathies such as Duchenne and Becker muscular dystrophy, and it has already completed Phase 1 testing. This program is the company's most recognized effort to date.

Alongside EDG-5506, Edgewise is advancing additional precision medicine candidates intended to act on specific muscle proteins, with the goal of treating other muscle disorders that have a defined genetic basis. The company's work centers on this pipeline of investigational compounds rather than on marketed products, reflecting a drug-development approach built around genetically targeted conditions.

Edgewise Therapeutics was founded in 2017 and is based in Boulder, Colorado. Its shares trade on the NASDAQ under the ticker EWTX.

Listed
NASDAQ
Sector
Health technology
Industry
Biotechnology
Website
edgewisetx.com

Edgewise Therapeutics GekkoIndex: the smart money zone

Edgewise Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 49.9, in the Neutral zone, up 1.8 points over five sessions.

010049.9Neutral

Up 1.8 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying14−0.2%+10.2%+16.1%+18.8%
Accumulation215+1.9%+3.3%+2.4%+5.1%
Neutral (current zone)428+1.1%+1.8%+5.1%+14.5%
Distribution33−3.8%−3.8%−2.4%+5.3%
Selling12+21.3%+28.3%+19.8%+17.9%

Average EWTX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the EWTX price, zone by zone.Track EWTX in Gekko

Is Edgewise Therapeutics stock overvalued? Gekko Fair Value

Edgewise Therapeutics trades 6.1% above Gekko Fair Value of $43.29, so the shares are overvalued on Gekko’s estimate.

Gekko’s own estimate of what Edgewise Therapeutics shares are worth, recalculated every trading day.

$43.29

Gekko Fair Value, Nov 14, 2026

6.1% Overvalued

At the end of Aug 2026 the price was 13.5% below the estimate.

Gekko Fair ValueShare price, month end
$43$46Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open EWTX in Gekko

Edgewise Therapeutics insider and Congress trading

No open-market insider purchases were filed for Edgewise Therapeutics, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for EWTX in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every EWTX insider filing, plotted on the chart in Gekko.Open EWTX in Gekko

Congress trades last 90 days

No trades in EWTX were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for EWTX, plotted on the chart in Gekko.Open EWTX in Gekko

Unusual options activity last 30 days

1signal, 100% of the flagged premium in calls.

Latest: Bullish flow on Nov 6, $1.11M in unusual premium.

Hedge funds and billionaires quarter ended Jun 30

0of the funds Gekko tracks hold EWTX.

0added0opened0trimmed3sold out
Every signal with its contract, strike and premium, and which funds are on each side.Unlock in Gekko

Edgewise Therapeutics earnings: next date and track record

Edgewise Therapeutics reports on Feb 25, 2027 (102 days away), and beat the EPS estimate in 5 of its last 8 reports.

5 of 8reports beat the EPS estimate
±3.3%average move across the report
3 of 8reports followed by a gain

Share-price move across each report

−6.4%Mar ’25+0.4%May ’25−6.2%Aug ’25−1.2%Nov ’25+1.1%Feb ’26−4.5%May ’26−3.3%Aug ’26+3.2%Nov ’26
ReportedEPSSurpriseRevenueSurpriseMove
Nov 4, 2026$9.65
est −$0.53
+1,915.3%—
est $119.2M
—+3.2%
Aug 6, 2026−$0.53
est −$0.48
−10.4%——−3.3%
May 7, 2026−$0.46
est −$0.48
+4.2%——−4.5%
Feb 26, 2026−$0.47
est −$0.43
−9.3%——+1.1%
Nov 6, 2025−$0.39
est −$0.40
+2.5%——−1.2%
Aug 7, 2025−$0.34
est −$0.42
+19.0%——−6.2%
May 8, 2025−$0.43
est −$0.42
−2.4%——+0.4%
Mar 3, 2025−$0.42
est −$0.42
+0.5%——−6.4%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Edgewise Therapeutics stock forecast and analyst price targets

Analysts’ average 12-month price target for Edgewise Therapeutics is $55.42, +20.7% from the last close, from 11 firms rating the stock in the last 90 days.

$55.42consensus 12-month target, +20.7% from the last close
Low $36High $85
Buy9
Hold2
Sell0

Each firm’s latest rating in the last 90 days: 11 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 9H.C. WainwrightBuy, maintained$57+24.1%
Nov 6WedbushBuy, maintained$51+11.0%
Nov 6Piper SandlerBuy, maintained$51+11.0%
Nov 5Stifel NicolausHold, reiterated$36−21.6%
Nov 5RBC CapitalBuy, reiterated$59+28.5%
+5.1%average 20-day move after past Neutral readings
−5.5%average move over the next 20 trading days in the last 5 years
±7.1%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Edgewise Therapeutics seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Edgewise Therapeutics averaged −5.5% across the last 5 years, rising in 2 of them.

Next 20 trading days, by year

−2.8%2021−23.0%2022+8.6%2023−16.0%2024+5.2%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days+0.7%1 of 5
Next 10 trading days−4.0%1 of 5
Next 15 trading days−2.3%3 of 5
Next 20 trading days−5.5%2 of 5
Next 30 trading days+5.3%2 of 5

For scale, EWTX’s typical 20-trading-day move in either direction is about 10.7%.

Edgewise Therapeutics market cap and key statistics

Edgewise Therapeutics’s market cap is $4.94B, with a P/E ratio of 5.5 and revenue of $0 over the last twelve months.

Valuation

Market cap
$4.94B
P/E ratio
5.5
EPS, TTM
$8.38
Gekko Fair Value
$43.29

Trading

Volume
1.16M
Avg volume, 20 days
1.67M
52-week high
$48.78
52-week low
$19.76
Shares outstanding
109.5M

Financials

Revenue, TTM
$0
Profit margin
0%
Return on equity
92.1%
Quarterly earnings growth, YoY
0.0%

Risk and income

Beta
0.40
Typical daily move
±7.1%
Typical 20-day move
±10.7%

Edgewise Therapeutics stock news this week

Coverage of Edgewise Therapeutics this week reads neutral: 1 positive, 4 neutral and 0 negative headlines.

News sentiment neutral

Edgewise Therapeutics peers

Edgewise Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
AMGNAmgen−0.4%Neutral19.9% below
GILDGilead Sciences−0.3%Neutral11.7% above
MRNAModerna−0.7%Neutral21.1% above
NTRANatera−1.8%Accumulation18.6% below
IQVIQVIA−2.4%Accumulation5.0% above
UTHRUnited Therapeutics−0.4%Neutral11.2% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Biotechnology

Edgewise Therapeutics stock FAQ

What is Edgewise Therapeutics’s market cap?

Edgewise Therapeutics’s market cap is $4.94B at the Nov 13, 2026 close of $45.93, with 109.5M shares outstanding. The shares trade on a P/E ratio of 5.5.

What is the Edgewise Therapeutics stock forecast?

The consensus analyst 12-month price target for Edgewise Therapeutics is $55.42, +20.7% from the last close. Of the 11 firms that rated the stock in the last 90 days, 9 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Edgewise Therapeutics stock overvalued or undervalued?

On Gekko’s estimate Edgewise Therapeutics is overvalued: the Nov 13, 2026 close of $45.93 is 6.1% above Gekko Fair Value of $43.29. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Edgewise Therapeutics report earnings next?

Edgewise Therapeutics is expected to report on Feb 25, 2027 (102 days away). Analysts expect earnings of −$0.43 per share on revenue of $9.62M. Edgewise Therapeutics beat the earnings estimate in 5 of its last 8 reports, moving 3.3% on average across the report.

What is Edgewise Therapeutics’s 52-week high and low?

Edgewise Therapeutics’s 52-week high is $48.78 and its 52-week low is $19.76; it closed at $45.93 on Nov 13, 2026, +117.0% over the past year.

Is Edgewise Therapeutics stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 6 items with data read as supportive (trend, smart money and earnings risk), 1 as mixed (gekkoindex) and 2 as headwinds (fair value and seasonality). The checklist is a description of current data, not a recommendation.

Is there unusual options activity in Edgewise Therapeutics?

Gekko flagged 1 unusual options signal in Edgewise Therapeutics over the last 30 days, with $1.11M of flagged premium in calls and $0 in puts. The latest, bullish flow, was on Nov 6, 2026 with $1.11M in unusual premium. The signal-by-signal table is in Gekko.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Edgewise Therapeutics the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.